Cytosorbents Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corporation (Nasdaq: CTSO) on April 7, 2021. The report details a corporate governance action taken by the Board of Directors on the same date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement and contains no financial performance data.
Material Changes
The Board of Directors approved and immediately enacted the Amended and Restated Bylaws of the Company. The primary material change is an amendment to Article II, Section 2.5 regarding the voting standard for the removal of directors. Under the revised bylaws, any director or the entire Board may be removed from office at any time, with or without cause, by the affirmative vote of the holders of the majority of the voting power of all outstanding shares entitled to vote generally in the election of directors, voting together as a single class.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly limited to the amendment of corporate bylaws.
Key Facts for Investor Verification
- The amendment to the Bylaws became effective immediately on April 7, 2021.
- The new standard allows for the removal of directors with or without cause by a majority vote of outstanding shares.
- The full text of the Amended and Restated Bylaws is attached as Exhibit 3.1 to the filing.
- The company is classified as an Emerging Growth Company.